Form 4: Krystal Biotech CEO Sells Shares Under 10b5-1 Plan

Krystal Biotech's President and CEO, Krish S. Krishnan, sold 25,928 shares of common stock on March 4, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Krish S. Krishnan, President and CEO, Director, and 10% Owner of Krystal Biotech, Inc. (KRYS), sold a total of 25,928 shares of common stock on March 4, 2026.
• The sales were executed at weighted average prices ranging from $257.3131 to $266.555 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 4, 2025, which commenced on December 4, 2025, and is set to terminate on December 4, 2026.
• Following these sales, Krish S. Krishnan directly beneficially owns 1,475,253 shares of common stock.
• Additionally, Krish S. Krishnan indirectly beneficially owns 90,000 shares through the Krishnan Spousal Trust and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to the volume of shares sold by a key insider, despite being under a 10b5-1 plan. While planned, it still represents a reduction in direct insider ownership.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a signal that an insider believes the stock price may be nearing a peak or that they are diversifying their holdings.
• A significant number of shares (25,928) were sold by a key executive and 10% owner.

Future Outlook

The Rule 10b5-1 trading plan, under which these sales occurred, is scheduled to terminate on December 4, 2026, or earlier if all shares subject to the plan are sold. This indicates a pre-planned divestment strategy over a defined period.

Management Comments

• The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
• The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
• The transaction was executed in multiple trades ranging from [price range]. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence for executives to manage personal finances, diversify portfolios, or exercise options. In the biotech sector, where stock volatility can be high, such planned sales are often a prudent financial strategy for long-term holders. However, the market often scrutinizes the timing and volume of such sales for any underlying signals about the company's near-term prospects.

Comparison to Industry Standards

• NA. This filing details an individual insider transaction rather than company performance metrics that can be directly compared to industry benchmarks or specific competitor results. The nature of a 10b5-1 plan is a standard practice for executives to avoid accusations of trading on material non-public information.

Related Party Transactions

• Krish S. Krishnan indirectly beneficially owns shares through the Krishnan Spousal Trust and Krishnan Family Trust, which are related entities.
• Holdings and transactions by the Krishnan Family Trust are also reflected on a separate Form 4 filed by his spouse, indicating joint beneficial ownership and control.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, potentially leading to short-term negative sentiment or increased scrutiny of the company's valuation.

Next Steps

• The Rule 10b5-1 trading plan is scheduled to terminate on December 4, 2026, or earlier upon completion of all planned sales.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Key Dates

Recommendation

While the insider selling by the CEO is a notable event, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the immediate negative implications of opportunistic selling. The company's underlying fundamentals and future prospects, which are not detailed in this Form 4, would be the primary drivers for a "buy" or "sell" recommendation. Without further information on the company's performance or strategic direction, a "hold" recommendation is appropriate, advising investors to monitor future filings and company news for a more comprehensive view.

Keywords

Krystal Biotech, KRYS, Insider Selling, Form 4, Krish S. Krishnan, 10b5-1 Plan, Stock Sale, Biotech, Executive Transaction